Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184198 | 1.00 | USP2 (0.43) | USP2SMN1; SMN2GPR119EPHX1NAMPT | |
| SCHEMBL22720242 | 0.86 | USP2 (0.43) | USP2SMN1; SMN2GPR119EPHX1NAMPT | |
| SCHEMBL1344048 | 0.79 | USP2 (0.50) | USP2SMN1; SMN2GPR119EPHX1NAMPT | |
| SCHEMBL30577865 | 0.76 | GPR119 (0.38) | USP2SMN1; SMN2GPR119NAMPTHPGD | |
| SCHEMBL29548956 | 0.76 | HPGD (0.48) | USP2SMN1; SMN2GPR119EPHX1NAMPT | |
| SCHEMBL19785380 | 0.75 | USP2 (0.44) | USP2SMN1; SMN2GPR119EPHX1NAMPT | |
| SCHEMBL30842433 | 0.75 | USP2 (0.50) | USP2SMN1; SMN2GPR119HPGDEPHX2 | |
| SCHEMBL16984146 | 0.75 | USP2 (0.50) | USP2SMN1; SMN2GPR119EPHX1NAMPT | |
| SCHEMBL8217780 | 0.75 | USP2 (0.50) | USP2SMN1; SMN2GPR119EPHX1NAMPT | |
| SCHEMBL21807018 | 0.74 | USP2 (0.49) | USP2SMN1; SMN2GPR119EPHX1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| CN-114206885-B | Pyrazolo [3,4-B ] pyrazines SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2025-05-02 | — | — | CN | disclosed |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| EP-4017855-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| CN-114206885-A | Pyrazolo [3,4-B ] pyrazine SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021033153-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-25 | — | — | WO | disclosed |
| EP-3310771-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| EP-3310774-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-06-04 | — | — | US | disclosed |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-09-06 | — | — | US | disclosed |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251471-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN3, PTPN1, PTPN2 | USP2 2277/4885SMN1; SMN2 1937/4885GPR119 716/4885 |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | PTPN5, PTPRZ1, PTPN1 | USP2 2048/4885SMN1; SMN2 3093/4885GPR119 1866/4885 |
| US-20180186770-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN2 | USP2 2147/4885SMN1; SMN2 2344/4885GPR119 630/4885 |
| US-10308660-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN3, PTPN1, PTPN2 | USP2 2277/4885SMN1; SMN2 1937/4885GPR119 716/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | USP2 2101/4885SMN1; SMN2 2037/4885GPR119 2016/4885 |
| US-10287266-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN3, PTPN2 | USP2 2225/4885SMN1; SMN2 2360/4885GPR119 650/4885 |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPRZ1, PTPN1 | USP2 2048/4885SMN1; SMN2 3093/4885GPR119 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.